NCT01187199 2026-04-16
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
178 trialsNCT02387905 2026-04-15
Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03671226 2026-04-15
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT04464226 2026-04-15
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Active not recruiting
NCT04957615 2026-04-15
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05347212 2026-04-15
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03768336 2026-04-14
A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors
Massachusetts General Hospital
Phase NA Active not recruiting
NCT04958239 2026-04-14
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05611632 2026-04-14
NHS-Galleri
GRAIL, Inc.
Phase NA Active not recruiting
NCT02908906 2026-04-13
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT03030378 2026-04-13
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03148418 2026-04-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04317105 2026-04-13
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04520711 2026-04-13
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
Phase 1 Active not recruiting
NCT04606381 2026-04-13
PALOMA
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05155605 2026-04-13
PATHFINDER 2: A Multi-Cancer Early Detection Study
GRAIL, Inc.
Phase NA Active not recruiting
NCT05554341 2026-04-13
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01706939 2026-04-09
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
Icahn School of Medicine at Mount Sinai
Phase 3 Active not recruiting
NCT04847466 2026-04-08
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05993299 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06703346 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06745024 2026-04-08
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT05975073 2026-04-07
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
Phase 1/2 Active not recruiting
NCT06939452 2026-04-07
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression
The First Affiliated Hospital of Zhengzhou University
Phase 2 Active not recruiting
NCT05112965 2026-04-06
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05261399 2026-04-06
SAFFRON
AstraZeneca
Phase 3 Active not recruiting
NCT05629234 2026-04-06
ROSY-T
AstraZeneca
Phase 3 Active not recruiting
NCT05784766 2026-04-06
SARIC
University of Oklahoma
Phase NA Active not recruiting
NCT02584933 2026-04-02
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Active not recruiting
NCT04713046 2026-04-02
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Active not recruiting
NCT06926972 2026-04-01
NOURISH
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Active not recruiting
NCT04538482 2026-03-27
DINING
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Active not recruiting
NCT04639219 2026-03-23
DPT01
AstraZeneca
Phase 2 Active not recruiting
NCT04419532 2026-03-20
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 1 Active not recruiting
NCT07474168 2026-03-16
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Zhejiang University
Phase 1 Active not recruiting
NCT04318886 2026-03-13
Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT
University of Alabama at Birmingham
Phase 3 Active not recruiting
NCT04803604 2026-03-12
CASCADE
University of Alabama at Birmingham
Phase NA Active not recruiting
NCT05763797 2026-03-11
Developing a Culturally Relevant Supportive Care Program for Black Patients Dealing With Advanced Cancer
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06864260 2026-03-11
PREEMpT
University of Alabama at Birmingham
Phase NA Active not recruiting
NCT05707910 2026-03-09
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
West China Hospital
Phase 1 Active not recruiting
NCT06549153 2026-03-09
ACT-Together (Acting on Cancer Testing-Together)
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT01428895 2026-03-06
Femoral Bone Metastases
University Health Network, Toronto
Phase NA Active not recruiting
NCT04913259 2026-03-03
TS-PAC
Institut Bergonié
Phase NA Active not recruiting
NCT04294628 2026-02-27
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03203525 2026-02-25
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT00750841 2026-02-23
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT05823740 2026-02-20
Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers
UNC Lineberger Comprehensive Cancer Center
Phase NA Active not recruiting
NCT03927885 2026-02-19
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
Phase 2/3 Active not recruiting
NCT04150900 2026-02-19
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
University of Maryland, Baltimore
Phase 2 Active not recruiting
NCT05396833 2026-02-19
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono
Phase 1 Active not recruiting